All In Biotech

NDA 217645 · Tris Pharma INC

Onyda Xr

Clonidine Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: May 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

May 24, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

276

54 Phase 3, 19 recruiting

FAERS reports

5,745

3,867 serious, 915 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 11, 2025.

ONYDA XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older [see Clinical Studies ( 14 )]. ONYDA XR is a centrally acting alpha 2 -adrenergic agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy or as adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older. ( 1 )

Mechanism: Clonidine stimulates alpha 2 -adrenergic receptors in the brain. Clonidine is not a central nervous system stimulant. The mechanism of action of clonidine in ADHD is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ONYDA XR · CLONIDINE HYDROCHLORIDE 0.1MG/ML · SUSPENSION, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Clonidine" as an intervention, any sponsor and status, largest first.

All 276 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypertension762
  • headache712
  • off label use695
  • pain639
  • fatigue635
  • hypersensitivity549
  • drug ineffective529
  • nausea477
  • infusion related reaction442
  • hepatic enzyme increased437
  • joint swelling425
  • rash415

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20055
20066
200710
200822
20098
201065
2011111
2012102
201367
201472
2015110
2016117
2017244
2018236
2019221
2020261
2021329
2022617
2023649
2024897
2025941
2026653

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,240 on PubMed

Sponsor: Tris Pharma INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.